Abstract

Vascular endothelial growth factor and epithelial cell adhesion molecule immunoexpression in enzootic nasal adenocarcinoma of goats

Abstract

Enzootic nasal adenocarcinoma (ENA) is a contagious and viral disease in sheep and goats. The disease leads to the death of the affected animals and causes economic losses in infected small ruminant flocks. Epithelial cell adhesion molecule (EpCAM) is a newly discovered tumor antigen, commonly expressed by several tumors occurring in humans. Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulate the formation of blood vessels and plays an important role in angiogenesis, essential for tumor development. In this study, ENA originating from the nasal mucosa is detected on histopathological and cytopathological examinations, with transmission electron microscopy confirming viral particles in the tumoral cells. The aim of this study was to examine VEGF and EpCAM immunoexpressions using streptavidin–biotin complex immunoperoxidase technique in 24 naturally ENA-affected goats. Sneezing, dyspnea, seromucous or purulent nasal discharge, exophthalmos, and weight loss were commonly observed clinical symptoms. The tumors located in the nasal cavity were generally unilateral and were bilateral in only two cases. Cytological examination of the tumoral masses revealed uniform epithelial cell clusters and abundant inflammatory reaction. On histopathological examination, tubular, papillary, or mixed types of ENA were diagnosed. On ultrastructural examination, intracytoplasmic, spherical, retrovirus-like particles were demonstrated. Immunohistochemically, strong positive reactions were reported for both EpCAM and VEGF in the cytoplasm of the tumor cells. Thus, this study showed that EpCAM and VEGF may have an important role in ENA pathogenesis.

Keywords

• Clinicopathology,enzootic nasal adenocarcinoma,pathogenesis,VEGF,EpCAM

References

1. 1. Akbulut H, Altuntas F (2002): Prognostic role of serum vascular endothelial growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine, 20, 184-190. 2. Aydogan A, Haligur M, Ozmen O (2013): Expressions of caspase-3, caspase-7, caspase-9 and cytokeratin AE1/AE3 in goats with enzootic nasal adenocarcinoma: an immunohistochemical study. Vet Med, 58, 417-421.
2. 3. Aydogan A, Ozmen O (2016): Expression of nectin-4 as a potential biomarker in enzootic, nasal adenocarcinoma of goats. Acta Vet Hung, 64, 71-77.
3. 4. Baeuerle PA, Gires O (2007): EpCAM (CD326) finding its role in cancer. Br J Cancer, 96, 417-423.
4. 5. Basak S, Speicher D, Eck S, et al (1998): Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer I, 90, 691-697.
5. 6. Bikfalvi A (2004): Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem Pharmacol, 68, 1017-1021.
6. 7. Broll R, Erdmann H, Duchrow M, et al (2001): Vascular endothelial growth factor (VEGF)- a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol, 27, 37-42.
7. 8. Bruns CJ, Liu W, Davis DW, et al (2000): Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer, 89, 488-499.
8. 9. Carmeliet P (2005): VEGF as a key mediator of angiogenesis in cancer. Oncology, 69, 4-10.

9. 10. Cimino A, Halushka M, Illei P, et al (2010): Epithelial cell adhesion molecule (EpCAM) is overex¬pressed in breast cancer metastases. Breast Cancer Res Treat, 123, 701-708.
10. 11. Cousens C, Minguijon E, Dalziel RG, et al (1999): Complete sequence of enzootic nasal tumor virus, a retrovirus associated with transmissible intranasal tumors of sheep. J Virol, 73, 3986-3993.
11. 12. De Las Heras M, Ortin A, Cousens C, et al (2003): Enzootic nasal adenocarcinoma of sheep and goats. Curr Top Microbiol Immunol, 275, 201-223.
12. 13. Duncan JR, Tyler DE, Van Der Mataten MJ, et al (1967): Enzootic nasal adenocarcinoma in sheep. JAVMA, 151, 732-734.
13. 14. Dunst J, Becker A, Lautenschlager C (2002): Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol, 178, 436-441.
14. 15. Falkman J, Watson K, Ingber D, et al (1989): Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, 58-61.
15. 16. Ferrara N, Gerber HP, Lecouter J (2003): The biology of VEGF and its receptors. Nat Med, 9, 669-676.
16. 17. Gasparini G, Harris AL (1995): Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol, 13, 7652-7682.
17. 18. Goel HL, Mercurio AM (2013): VEGF targets the tumour cell. Nat Rev Cancer, 13, 871-882.
18. 19. Guinan P, Saffrin R, Stuhldreher D, et al (1995): Renal cell carcinoma: comparison of the TNM and Robson stage groupings. J Surg Oncol, 59,186-189.
19. 20. Huang L, Yang Y, Yang F, et al (2018): Functions of EpCAM in physiological processes and diseases (Review). Int J Mol Med, 42, 1771-1785.
20. 21. Kwon KA, Kim SH, Oh SY (2010): Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reative protein level in colorectal cancer. BMC Cancer, 14, 203.
21. 22. Lee JS, Kim HS, Jung JJ (2002): Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. Appl Immunohistochem Mol Morphol, 10, 289-295.
22. 23. Lee SJ, Chung KY, Kwon JE, et al. (2018): Expression of EpCAM in adenoid cystic carcinoma. Pathology, 50 737-741.
23. 24. Luna GL (1968): Manual of histologic staining methods of the armed forces institute of pathology. McGraw Hill Book Co. New York.
24. 25. Maetzel D, Denzel S, Mack B (2009): Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol, 11,162-171.
25. 26. Mall JW, Schwenk W, Philipp AW et al (2002): Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuronspecific enolase or lactate dehydrogenase. Respirology, 7, 99-102.
26. 27. Mercurio AM (2019): VEGF/neuropilin signaling in cancer stem cells. Int J Mol Sci, 20, 490.
27. 28. Neufeld G, Cohen T, Gengrinovitch S, et al (1999): Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 13, 9-22.
28. 29. Osta WA, Chen Y, Mikhitarian K, et al (2004): EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res, 16, 5818-5824.
29. 30. Ozmen O, Sahinduran S, Haligur M, et al (2010): Clinical, pathological, immunohistochemical and ultrastructural observations on Enzootic Nasal Adenocarcinoma in five goats. Kafkas Univ Vet Fak Derg, 16, 633-639.
30. 31. Ozmen O, Serpin N (2016): First case of Enzootic Nasal Adenocarcinoma (ENA) in a sheep in Turkey. MAE Vet Fak Derg, 1, 87-90.
31. 32. Sahinduran S, Ozmen O, Kıyıcı R (2018): Determination of telomerase enzyme level in Enzootic Intranasal Tumors of goats. Kafkas Univ Vet Fak Derg, 24, 583-588.
32. 33. Salven P, Orpana A, Joensuu H (1999): Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res, 5, 487-491.
33. 34. Serpin N, Ozmen O (2016): Koyun ve keçilerde Enzootik Nazal Adenokarsinom’da (ENA) patolojik incelemeler. MAE Vet Fak Derg, 1, 21-28.
34. 35. Toi M, Hoshiva S, Takayanagi T, et al (1994): Association of vascular endothelial growth factor expression with tumor angiogenesis and with early release in primary breast cancer. Jpn J Cancer Res, 85, 1045-1049.
35. 36. Vincenti V, Cassano C, Rocchi M (1996): Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation, 93, 1493-1495.